a2g - congratulations, your seventh post on HC and your seventh post on GBI.
You really must have quite a deep interest in the company!
It is a very interesting journal article that you post, and one that is generally very supportive of a genotyping test being used as the primary cervical screening method in due course. Potentially a huge market.
We know that the current clinical study being undertaken by GBI is not on 6,700 patients, but instead on circa 900.
However, given that this population is a triage population rather than a screening population, I would expect that it would contain many more than 134 CIN2+ specimens. i am not sure what this would do to your assertions re population size - more CIN2+, less absolute number of specimens. Maybe you could elaborate??
I recall that back in June GBI also stated that it was going to be doing a couple of further studies, one on a screening population of samples that RWH has in the fridge. Another to be undertaken on an American screening population - don't know where these samples are coming from.
I don't recall whether sizes of these studies were disclosed, but presumably a few thousand samples in these combined?? Which should get you much closer to the 6,700 in aggregate.
A couple of further points:
a) We all know that GBI is not doing a study that would qualify PapType for FDA registration. To do so would cost tens of millions. Nobody has ever pretended otherwise.
b) there is a presumption by a couple of the self proclaimed experts on this thread - you and liqcrisis - that GBI is a mickey mouse operation and doesn't really know what it is doing. This may be the case, but the WEHI pedigree of the science is pretty good and the RWH is a solid partner to have on the clinical studies - they are a WHO reference site for HPV and pretty well versed in the area.
c) as for your assertions regarding what potential partners would think of a clinical study with certain clinical parameters. . . . well, you are guessing. You are essentially asserting that anything less than a full FDA study is going to be insufficient to attract any interest. If GBI had a completed FDA study it would be worth something approaching $500 million. . . . just like Third Wave.
Let's wait and see. Only time will tell.
- Forums
- ASX - By Stock
- GBI
- hpv genotyping trial design
hpv genotyping trial design, page-2
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GBI (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online